Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD

NCT06668064 is registered in ClinicalTrials.gov with EyePoint Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06668064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06668064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 22, 2024
Completion date
August 31, 2027
Enrollment
400 (estimated)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

wamd, wet age related macular degeneration